Delivering Most-favored-nation Prescription Drug

The order seeks to reduce U.S. prescription drug and biologic prices by pressing manufacturers to match prices in comparable developed countries and threatening regulatory, trade, importation, and antitrust action if progress falls short.

What the order does ​

• Requires federal officials to give pharmaceutical manufacturers most-favored-nation price targets within 30 days.
• Directs the government to facilitate direct-to-consumer sales at most-favored-nation prices where legally permitted.
• Orders trade officials to address foreign policies that suppress drug prices and shift disproportionate research costs to Americans.
• Requires a rulemaking plan for most-favored-nation pricing if manufacturers do not make significant progress.
• Directs officials to consider expanded case-by-case drug importation, pharmaceutical export restrictions, antitrust enforcement, and review of drug approvals if progress is insufficient.

Who it affects ​

• Americans who buy prescription drugs and biologics.
• Pharmaceutical manufacturers selling in the United States and abroad.
• Public and private healthcare payers and foreign countries with lower pharmaceutical prices.